Atorvastatin †Rx

Lipophilic statin that blocks mevalonate/isoprenoids → impaired prenylation (Rho/Ras/Rac), reduced migration/metastasis, and context-dependent apoptosis; useful as an adjunct in resistant disease.

← All agents

Human-reviewed · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed

👥⭐⭐⭐ Moderate — Human data in ovarian/breast and observational signals across cancers; most robust as an adjunct, with promise in resistant disease.LipitorStatin (atorvastatin)

Forms: Atorvastatin tablets (10–80 mg)

Educational only, not medical advice. OncoForge makes no claim that Atorvastatin †Rx treats, prevents, or cures any condition, beyond what the linked studies show. Evidence levels vary; effects may not translate to people, and some compounds can cause harm. Always coordinate with your oncology team.

Simple Summary

A familiar cholesterol drug with anticancer promise: by shutting down the mevalonate pathway, atorvastatin starves tumors of prenylation needed for growth and spread. That can slow migration/metastasis programs and promote apoptosis, and it may enhance chemo or immunotherapy—especially in resistant tumors.

Evidence at a glance

Tier 3 · early humanOvarian (platinum-resistant)BreastNSCLC (adjunct)Colorectal (preventive)Lung (ICI adjunct)Various (observational)

Multiple human observational/early interventional signals; randomized oncology outcome data remain limited but resistance settings show promise.

How it may work

Atorvastatin inhibits HMG-CoA reductase, blocking the mevalonate pathway and depleting isoprenoids (FPP/GGPP) required to prenylate small GTPases (Rho/Rac/Ras). Loss of prenylation impairs membrane localization and signaling that drive proliferation, survival, migration, invasion, and therapy resistance. Downstream, this can reduce NF-κB/AKT signaling, lower MMPs/adhesion, curb angiogenesis, and tip cells toward apoptosis. Clinical interest is strongest in drug-resistant disease and as an adjunct to DNA-damaging agents and immunotherapy.

Targets & pathways

Curated mechanistic targets reported for this agent — how it may act on cells, not proof of a clinical effect.

Mevalonate pathway↓
HMG-CoA reductase↓
RhoA/Rac1/Ras prenylation↓Membrane localization/signaling impaired
Migration/Invasion↓Adhesion/MMP programs reduced
Metastatic potential↓
AKT/NF-κB signaling↓
Apoptosis↑
Angiogenesis↓

MevalonateRhoInvasion/MetastasisApoptosis

Often studied / combined with

Combinations reported in the literature, not a protocol or a recommendation.

Disulfiram: Potential complementary redox/copper toxicity; mevalonate block may heighten stress—limited direct data.
Metformin: Metabolic/mTOR co-targeting.
Checkpoint inhibitors: Mevalonate/TME effects may support response in some contexts.

Overlapping mechanisms

Mevalonate ↓: Avoid combining multiple statins; if using a statin + bisphosphonate (mevalonate-adjacent), monitor for additive AEs.

Safety & interactions

Severity and how well-established each signal is are shown separately. Verify everything with your oncologist or pharmacist — absence here does not mean safe.

Risk categories

Hepatotoxicity RiskMyopathy RiskNew Onset Diabetes Risk MildPregnancy Avoid

Potential interactions

strong CYP3A4 inhibitors (e.g., clarithromycin, azoles, HIV protease inhibitors), grapefruit juiceAvoidMajorTheoretical↑ Atorvastatin exposure → myopathy/rhabdo risk.
fibrates (esp. gemfibrozil)AvoidMajorTheoreticalAdditive myopathy risk; choose alternatives if lipid therapy needed.
checkpoint inhibitors / cytotoxic chemotherapyMonitorMinorTheoreticalPotential adjunct benefit; monitor for liver/muscle AEs.

Timing

Anytime: Long half-life; food independent.
PM: Optional; some clinicians prefer evening though not required for atorvastatin.

References

Research

No published studies for Atorvastatin †Rx yet

New studies appear here once they’ve been reviewed. Browse all studies.

Dose: as studied, not a recommendation

These are doses as studied or reported, never a recommendation. The right amount of Atorvastatin †Rx depends on you, your other medicines, and your situation; decide it with your oncology team and pharmacist, not from a web page.

Ranges seen in adjunct / practice use: 10–80 mg (po) Once daily. Oncology adjunct studies often use 40–80 mg qd under supervision., Rx only. Baseline LFTs and symptom monitoring recommended; consider higher end of range for investigational adjunct protocols if clinician approves..

Trials studying Atorvastatin †Rx

No actively-recruiting trials matched right now. Recruiting is not the same as proven. Search ClinicalTrials.gov →

Appears in these protocol claims

Atorvastatin †Rx is named in these protocols discussed online. Listed for transparency: being part of a protocol is not evidence that it works, and OncoForge does not endorse them.

Ivermectin / Benzimidazole Protocol Claims : Aggressive online protocols combining ivermectin with fenbendazole or mebendazole.
Jane McLelland / Metabolic Blocking Claims : Multi-pathway metabolic strategy based around starving cancer fuel routes and blocking escape pathways.
Care Oncology-Style Repurposed Drug Claims : Clinic-associated repurposed-drug approach often discussed around four common medications.

Inclusion here is not an endorsement. OncoForge makes no claim beyond what the linked studies show. Discuss anything on this page with your oncology team before acting on it.

← All agents · Research Radar